Committed to Making a Difference in the Lives of Patients with Rare Diseases
Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
Guided by our core values of patients, science and passion, we utilize our TransCon™ technology to create new and potentially best-in-class therapies. We currently have a pipeline of three wholly-owned, independent rare disease endocrinology product candidates in clinical development.
TransCon Growth Hormone
TransCon Growth Hormone is being evaluated as a once-weekly therapy for children with growth hormone deficiency. Top-line results for our phase 3 heiGHt Trial are expected in the first quarter of 2019. Learn More
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (short from “transient conjugation”) to create best-in-class products to address unmet patient needs. Watch Video
News & Events
Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results
November 28, 2018 - Read More